2021 Q4 Form 10-Q Financial Statement

#000165495422000549 Filed on January 18, 2022

View on sec.gov

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20853000	shares
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	452622	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	71667	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	15007	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	35055	USD
CY2021Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	145000	USD
CY2021Q1	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	0	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	275000	USD
CY2021Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	0	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	8548	USD
CY2021Q1	us-gaap	Interest Receivable InterestReceivable	0	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	168555	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	35055	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2050	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9967	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	857990	USD
CY2021Q1	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	0	USD
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	870007	USD
CY2021Q1	us-gaap	Noncurrent Assets NoncurrentAssets	0	USD
CY2021Q4	us-gaap	Assets Assets	1038562	USD
CY2021Q1	us-gaap	Assets Assets	35055	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	85223	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	36486	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31727	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35181	USD
CY2021Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	10672	USD
CY2021Q4	us-gaap	Liabilities Liabilities	452622	USD
CY2021Q1	us-gaap	Liabilities Liabilities	71667	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20853000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19590000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20853	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	19590	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2938729	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1591283	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2373642	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1647485	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	585940	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36612	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1038562	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35055	USD
CY2021Q4	us-gaap	Cost Of Revenue CostOfRevenue	13289	USD
CY2020Q4	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	28942	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2009	USD
CY2020Q4	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	28942	USD
	us-gaap	Revenues Revenues	2009	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	115574	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20512	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	469373	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1479019	USD
CY2020Q4	us-gaap	Professional Fees ProfessionalFees	39393	USD
	us-gaap	Professional Fees ProfessionalFees	274258	USD
	us-gaap	Professional Fees ProfessionalFees	96824	USD
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	102283	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-204568	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-59905	USD
	us-gaap	Operating Expenses OperatingExpenses	743631	USD
	us-gaap	Operating Expenses OperatingExpenses	1575843	USD
CY2021Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	217857	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	59905	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-714689	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1573834	USD
CY2021Q4	us-gaap	Interest Income Operating InterestIncomeOperating	2992	USD
CY2020Q4	us-gaap	Interest Income Operating InterestIncomeOperating	0	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	8548	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	0	USD
CY2021Q4	us-gaap	Costs And Expenses CostsAndExpenses	8547	USD
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	0	USD
	us-gaap	Costs And Expenses CostsAndExpenses	20016	USD
	us-gaap	Costs And Expenses CostsAndExpenses	0	USD
CY2021Q4	us-gaap	Other Income OtherIncome	-5555	USD
CY2020Q4	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	-11468	USD
	us-gaap	Other Income OtherIncome	0	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-210123	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-59905	USD
	us-gaap	Net Income Loss NetIncomeLoss	-726157	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1573834	USD
CY2021Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20853000	shares
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19590000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20133047	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19590000	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36612	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30420	USD
CY2021Q2	hbr	Common Shares And Warrants Issued For License Amount CommonSharesAndWarrantsIssuedForLicenseAmount	38500	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	252852	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-340414	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-55254	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55746	USD
CY2021Q3	hbr	Common Shares And Warrants Issued For License Amount CommonSharesAndWarrantsIssuedForLicenseAmount	857990	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	69989	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-175620	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	752851	USD
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	43212	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-210123	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	585940	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	172843	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-44292	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	128551	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1417640	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1469637	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	76554	USD
CY2020Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1417640	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-59905	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1434289	USD
	us-gaap	Net Income Loss NetIncomeLoss	-726157	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1573834	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	366053	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1417640	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-125000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	50000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2050	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	87237	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	49447	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3454	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4151	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-236214	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106747	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	-200000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4856	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	USD
	hbr	Note Receivable Impairment NoteReceivableImpairment	50000	USD
	hbr	Note Receivable Impairment NoteReceivableImpairment	0	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-8548	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86166	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	411166	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-20048	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-106747	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35055	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172843	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15007	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66096	USD
	us-gaap	Interest Paid InterestPaid	3666	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	38500	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	857990	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	hbr	Capitalization Of Rou Asset And Liability Operating CapitalizationOfRouAssetAndLiabilityOperating	14823	USD
	hbr	Capitalization Of Rou Asset And Liability Operating CapitalizationOfRouAssetAndLiabilityOperating	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1. NATURE OF BUSINESS AND GOING CONCERN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 9, 2019 (commencement of operations), Healthcare Business Resources, Inc. (“we”, “our”, the “Company”), a domestic corporation was organized in Delaware to provide consulting services to healthcare organizations. These services include management consulting related to sales, marketing, business development and advisory board function. The Company’s services are designed to help clients increase revenue, improve overall efficiency and effectiveness of their operations and grow strategically.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 5, 2021, HBR Pointclear, LLC, a Delaware limited liability company was incorporated. HBR Pointclear, LLC was formed to enter into an Option Agreement to Purchase Business Assets with PointClear Solutions, Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 18, 2021, we and HBR Sub, Inc., a Delaware corporation and our wholly owned subsidiary entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with UserTech U.S. LLC, a Delaware limited liability company (“UPlus”) and UPlus Health, LLC, a Delaware limited liability company and a wholly-owned subsidiary of UPlus (“UPlus Health”). Pursuant to the Merger Agreement, and subject to the terms and conditions contained therein, HBR Sub, Inc. was merged with and into UPlus Health, with UPlus Health surviving the merger on the terms and subject to the conditions set forth in the Merger Agreement and certain ancillary agreements. UPlus Health is now our Company’s wholly owned subsidiary. UPlus helps companies across multiple industries with continuous innovation and market development through the implementation of its proprietary technology called the U+Method, which is a is a step-by-step product development methodology that focuses on front–loading the risky parts of product development before starting large buildouts (the “U+Method Technology”). UPlus has licensed to UPlus Health the U+Method Technology and related intellectual property for use in the health care and medical services industry (the “Medical Industry”), pursuant to the license attached to the Merger Agreement as Exhibit A (the “License Agreement”). UPlus and the Company believe that their individual capabilities and expertise could be combined to provide a unique integrated solution to clients in the Medical Industry; and UPlus’ post transaction participation in providing the anticipated integrated solution is set forth in the services agreement (the “Services Agreement”), a copy of which is set forth as Exhibit B to the Merger Agreement. The Company’s post transaction financial metrics plan for UPlus Health and the anticipated integrated solution is set forth in UPlus Health’s financial metrics plan (“Financial Metrics Plan”), a copy of which is set forth as Exhibit C to the Agreement. UPlus Health will be managed by the Company’s current management team.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consideration for the merger consisted of our Company’s issuance to UPlus of 1,000,000 shares of our common stock and a three-year warrant to purchase 1,400,000 shares of our common stock for $0.50 per share, subject to the Special Adjustments described in the Merger Agreement, which includes UPlus’ right to unwind the merger in the event we fail to meet the Financial Metrics Plan described in the Merger Agreement. As of August 31, 2021, the total purchase price for the acquisition was determined to be $857,990, which consisted of 1,000,000 shares of common stock with a fair value of $500,000 and 1,400,000 stock warrants with a fair value of $357,990. The Company concluded the transaction qualified as an asset acquisition and all such acquisition costs have been capitalized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In this filing, unless context requires otherwise, references to “we,” “our,” “us” and “our Company” refer to Healthcare Business Resources Inc., a Delaware corporation, and its subsidiaries HBR Pointclear, LLC, HBR Business Development, LLC and UPlus Health, LLC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Liquidity and Going Concern</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern twelve months from the issuance of these consolidated financial statements. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, or other third-party funding.</p>
CY2021Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	150000	USD
CY2021Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	150000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	50000	USD
CY2021Q4	us-gaap	Due From Related Parties DueFromRelatedParties	8548	USD
CY2021Q4	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	25000	USD
CY2021Q3	us-gaap	Debt Instrument Description DebtInstrumentDescription	Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $150,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid
CY2021Q3	us-gaap	Unsecured Debt UnsecuredDebt	150000	USD
	hbr	Schedule Of Stock Warrant Activity ScheduleOfStockWarrantActivity	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Outstanding at February 28, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Forfeited and expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Outstanding at November 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q4	hbr	Lease Expense LeaseExpense	2881	USD
	hbr	Lease Expense LeaseExpense	4805	USD
CY2021Q4	hbr	Long Term Debt Maturities Repayments Of Principal In Next Rolling LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRolling	1025	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	10250	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11275	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10672	USD
CY2021Q4	hbr	Consideration Amount Of Shares ConsiderationAmountOfShares	10.00
CY2021Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	32000	shares

Files In Submission

Name	View Source	Status
0001654954-22-000549-index-headers.html	Edgar Link	pending
0001654954-22-000549-index.html	Edgar Link	pending
0001654954-22-000549.txt	Edgar Link	pending
0001654954-22-000549-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbr-20211130.xsd	Edgar Link	pending
hbr-20211130_cal.xml	Edgar Link	unprocessable
hbr-20211130_def.xml	Edgar Link	unprocessable
hbr-20211130_lab.xml	Edgar Link	unprocessable
hbr-20211130_pre.xml	Edgar Link	unprocessable
hbr_10q.htm	Edgar Link	pending
hbr_10q_htm.xml	Edgar Link	completed
hbr_ex109.htm	Edgar Link	pending
hbr_ex109img66.jpg	Edgar Link	pending
hbr_ex109img67.jpg	Edgar Link	pending
hbr_ex109img68.jpg	Edgar Link	pending
hbr_ex109img69.jpg	Edgar Link	pending
hbr_ex109img70.jpg	Edgar Link	pending
hbr_ex109img71.jpg	Edgar Link	pending
hbr_ex109img72.jpg	Edgar Link	pending
hbr_ex109img73.jpg	Edgar Link	pending
hbr_ex109img74.jpg	Edgar Link	pending
hbr_ex109img75.jpg	Edgar Link	pending
hbr_ex109img76.jpg	Edgar Link	pending
hbr_ex109img77.jpg	Edgar Link	pending
hbr_ex109img78.jpg	Edgar Link	pending
hbr_ex109img79.jpg	Edgar Link	pending
hbr_ex109img80.jpg	Edgar Link	pending
hbr_ex109img81.jpg	Edgar Link	pending
hbr_ex109img82.jpg	Edgar Link	pending
hbr_ex109img83.jpg	Edgar Link	pending
hbr_ex109img84.jpg	Edgar Link	pending
hbr_ex109img85.jpg	Edgar Link	pending
hbr_ex109img86.jpg	Edgar Link	pending
hbr_ex109img87.jpg	Edgar Link	pending
hbr_ex109img88.jpg	Edgar Link	pending
hbr_ex311.htm	Edgar Link	pending
hbr_ex312.htm	Edgar Link	pending
hbr_ex321.htm	Edgar Link	pending
hbr_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending